Want to see TSE:VXL full AI Analyst Report?
VXL Stock Chart & Stats
C$0.17
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.17
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
C$697.20K
Enterprise ValueC$0.07
Total Cash (Recent Filing)C$527.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)1.3
Beta-1.01
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero total debt reduces solvency and interest burden, giving durable financial flexibility during lengthy clinical development. For a clinical-stage biotech, a debt-free structure lowers fixed financing costs and preserves optionality to fund trials via equity or partnerships.
Improving Cash Burn TrendCash burn moderation versus earlier years signals improving cost discipline and lower monthly funding needs. While still negative, this durable improvement can extend runway, reduce near-term financing pressure, and increase the odds of reaching clinical milestones without disruptive pivots.
Clinical-stage Immunotherapy FocusA focus on immunotherapy and T‑cell approaches in oncology and infectious disease aligns with structural demand and high unmet need. As a clinical-stage developer, success on milestone-driven programs leverages durable scientific interest and can create substantial strategic partnership opportunities.
Bears Say
No Reported RevenueAbsence of any reported revenue leaves the company unable to validate commercial demand or self-fund development. Over a 2–6 month horizon this constrains strategic options, raises dilution risk from financing, and lengthens the timeline to prove sustainable business economics.
Persistent Negative Operating And Free Cash FlowConsistently negative operating and free cash flow (~-267k TTM) shows the business is not self-sustaining and will rely on external funding. Persistent cash burn pressures can delay trials, force trade-offs in program spend, and increase vulnerability to market-financing cycles.
Operating Losses And Volatile Net IncomeRecurring negative EBIT and swings in net income—recent positives driven by non-operating items—indicate weak earnings quality. This volatility undermines predictability for planning, complicates partner negotiations, and raises uncertainty about repeatable operating performance.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.29 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$697.20K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 29 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Currently, no data Available
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,021 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―